During the 2000-2001 season in Canada, a newly identified oculorespiratory syndrome (ORS) was observed in patients after
immunization with inactivated influenza vaccine. ORS was associated with a high proportion of microaggregates of unsplit virions in the implicated vaccine and had clinical features suggesting delayed-onset hypersensitivity. We explore the association between in vitro cytokine balance (type 1 vs. type 2) and clinical ORS after influenza vaccination. We report the balance of interferon (IFN)-g, interleukin (IL)-10, IL-5, and IL-13 expression by peripheral blood mononuclear cells (PBMC) among unvaccinated, vaccinated ORS-affected, and vaccinated ORS-unaffected persons after in vitro challenge with implicated and nonimplicated vaccines. Antigen-stimulated PBMC from vaccinated persons produced significantly more IFN-g than did those from unvaccinated persons. There was a statistically significant type 2 polarization among unvaccinated compared with vaccinated persons. Although vaccinated ORS-affected individuals had less of a type 1 basis than did vaccinated unaffected individuals, this difference was not statistically significant.
During the 2000-2001 season, a newly identified oculorespiratory syndrome (ORS) was detected across Canada as an ad-verse effect of influenza vaccine. Persons with ORS developed bilateral red eyes, respiratory symptoms (including cough, wheeze, chest tightness, difficulty breathing, or sore throat), or facial edema beginning 2-24 h after receipt of influenza vaccine [1] [2] [3] [4] . More than 900 reports were made during 2000-2001; 96% were associated with a single manufacturer's influenza vaccine (A), and only a minority were associated with a second manufacturer of influenza vaccines (B and C) for Canada [1, 3, 4] .
The risk of ORS was significantly greater for women, persons aged 40-59 years, and those vaccinated against influenza for the first time in 2000 [1] [2] [3] [4] . Persons with underlying lung disease or allergies were more likely to cite prolonged or severe symptoms [5] . All influenza vaccines contained only killed virus, but a higher proportion of aggregated unsplit virions was found in the implicated vaccine, with all lots affected [3] .
The immune mechanism underlying ORS remains unknown. One hypothesis suggested excess IFN release [3] . Inactivated split influenza vaccines stimulate cell-mediated response but to a lesser degree than whole or live vaccines [6] [7] [8] . In mouse models, the cytokine response to inactivated influenza vaccine has been characterized as type 2, but others have described a type 1 response in humans that varies with the vaccine preparation (whole or split) and with the age of the vaccinated subject [9] [10] [11] [12] . It is unclear how aggregates of unsplit virions may influence this response.
Because ORS has clinical and epidemiological features suggestive of hypersensitivity, we hypothesized that the underlying immune response was biased to a type 2 phenotype. We assessed this by in vitro challenge of peripheral blood mononuclear cells (PBMC) with influenza antigen via cytokine and antibody response.
Subjects, materials, and methods Subjects in each of 3 groups were recruited: (1) Exclusions to enrollment included pregnancy, diseases of the immune system, or immunosuppressive therapy. The ethics board for the University of British Columbia approved the study.
Heparinized venous whole blood was collected. PBMC were purified from blood with Ficoll-hypaque. Cell viability was assured by trypan blue exclusion. Cell concentrations were adjusted to 6 /mL in RPMI-10 (RPMI-1640, 10% human 1.5 ϫ 10 AB serum, 50 mM b-mercaptoethanol, 2 mM l-glutamine, penicillin 100 U/mL, and streptomycin 100 mg/mL). One hundred eighty microliters of cell suspension ( Both vaccines also contained 0.01% thimerosol and trace amounts of egg proteins and formaldehyde. Vaccine A also contained trace residual amounts of gelatin 0.05% and deoxycholate as a splitting agent. Vaccine B contained trace residual amounts of Triton X-100 as a splitting agent.
Three in vitro PBMC culture conditions were established (vaccines A or B or medium alone) by adding antigen in 20 mL of RPMI-10 for final dilution of 1:1000 (∼15 ng of each influenza antigen/well) or medium only as control. Optimal dilution was established during prior pilot testing; lower dilutions of vaccine were toxic to PBMC. PBMC were cultured for an additional 2 and 5 days, and supernatants were harvested and stored at Ϫ80ЊC for cytokine assay.
All supernatants at day 5 were assayed by ELISA (PharMingen) for IFN-g (as type 1 marker), IL-4, IL-5, IL-10, and IL-13 (as type 2 markers). All assays were run in duplicate in parallel and the average recorded by a technologist blind to vaccination group. Undetectable cytokine levels were arbitrarily assigned a consistent concentration value between zero and the minimal level of detection for the ELISA-based cytokine assay for IFN-g, IL-10, IL-5, and IL-13 (4, 4, 2, and 1 pg/mL, respectively).
A single serum sample was collected at the same visit. Serum samples were tested for residual hemagglutinin-inhibiting (HI) antibodies against components of the 2000-2001 influenza vaccine, using standard microtiter assay.
Dependent variables exhibiting considerable skew in the raw form were log transformed. Adjustment for cytokine expression in medium (CEM) alone was calculated as log(cytokine vaccine challenge :cytokine medium ). As markers of the type 1:type 2 balance, log(IFN-g:IL-10), log(IFN-g:IL-13), and log(IFN-g:IL-5) ratios were computed.
Data were explored using standard box plots [13] . Cytokine results adjusted for CEM were compared by vaccine (A or B) and group. Statistical significance was assessed by least squares, including an interaction term, an adjustment for correlation within subjects, and a different variance for each group. Modelbased effect estimates with standard errors were produced. Additional covariates such as age, sex, previous influenza immunization, and allergy history were explored.
Geometric mean titers (GMTs) of antibodies (and 95% CIs) and the proportion with protective titers (у1:40) were determined. Least squares was used to assess the effect of vaccination group on log transformed HI antibody titers.
was se-P ! .05 lected as the level of statistical significance.
Results. PBMC were assessed from 16 unvaccinated, 18 vaccinated unaffected, and 21 vaccinated affected persons, respectively. Median ages were 47, 50, and 47 years, respectively ( ). The percentage of females did not vary (69%, 72%, P p .9 and 71%, respectively;
). The median number of influ-P p .9 enza immunizations received prior to 2000-2001 was 1 for the vaccinated affected and 3 for the vaccinated unaffected individuals ( ); more of the vaccinated affected compared P ! .0001 with the vaccinated unaffected reported immunization in 2000 as the first-ever dose (38% vs. 6%;
). Among affected P p .02 persons, 2 experienced red eyes alone, 7 respiratory symptoms alone, and the remainder a combination of ocular, respiratory, or facial symptoms after vaccination in 2000.
The IL-4 response was undetectable and is not presented. Vaccinated unaffected persons produced 4.5-fold more IFN-g ( ) than did the unvaccinated. Vaccinated affected per-P p .0009 sons produced 3-fold more IFN-g than did unvaccinated persons ( ) (table 1) . The difference in IFN-g production P p .03 between vaccinated affected and vaccinated unaffected groups was not significant ( ). The IFN-g expression stimulated P p .5 by vaccines A or B did not differ ( ) ( figure 1A ). There P p .3 was no interaction between vaccination group and vaccine product ( ). P p . 7 No difference between vaccination groups in the expression of IL-10, IL-13, or IL-5 was statistically significant ( , .8, P p .2 and .5, respectively). Vaccine A stimulated more IL-10 than did vaccine B ( ) for all groups, but this was not so for IL-P p .02 13 ( ) or IL-5 ( ) ( figure 1A ). Neither the number P p .7 P p .5 of previous influenza immunizations nor atopic history had significant effect on cytokine expression.
The log(IFN-g:IL-10) ratio was significantly higher in both the vaccinated unaffected ( ) and the vaccinated af-P p .005 fected ( ) compared with the unvaccinated (table 1) . P p .02 Similarly, the log(IFN-g:IL-13) ratio was higher in both the vaccinated unaffected ( ) and the vaccinated affected P p .0003 ( ) relative to the unvaccinated. The same pattern was P p .004 found for log(IFN-g:IL-5) ( and .002, respectively) P p .008 Although the type 1:type 2 balance was consistently lower among the vaccinated affected compared with the vaccinated unaffected, these differences were not statistically significant ( , .6, and .8, respectively) ( figure 1B) .
The Discussion. Understanding the immunologic impact of aggregated virions in influenza vaccine is important from a public health perspective, particularly in relation to ORS. Controlled clinical trials have shown a 10-fold higher risk of ORS after revaccination with 2001-2002 vaccine for previously affected compared with previously unaffected persons, despite changes to the manufacturing process and reduced microaggregate content of the implicated vaccine [4] . A recurrence risk, not anaphylactic in nature, has also been observed in skin test evaluation [14] . These results suggest interactions with the acquired immune response and long-term recall that are important to characterize [15] .
Our study confirms that inactivated split influenza vaccination elicits substantial cell-mediated immunity and cytokine response. PBMC of vaccinated persons demonstrate significant IFN-g booster on rechallenge in vitro compared with PBMC of unvaccinated persons. Although a similar booster effect was not seen for other cytokines, pilot testing was originally based on IFN-g measurement. Detailed kinetic studies may provide the enhanced sensitivity for detection of additional changes in recall response.
Large nonphagocytosable antigens are known to stimulate type 2 polarization. Female hormones and preexisting cytokine milieu can predispose toward type 2 immunity [15] . A relationship between ORS and type 2 polarization is not ruled out by our study; sample size may not have been sufficient for statistical proof. IL-4 is the prototype cytokine for assessing type 2 response, but we were unable to detect this cytokine by ELISA-instead, ultrasensitive assays are required. A trend toward relative type 2 polarization may be suggested by other findings. The implicated vaccine stimulated significantly more IL-10 than did vaccine B across all categories of participants. A single antibody titer 6 months after vaccination showed elevated response to A/Panama and A/New Caledonia among the ORS-affected relative to the unaffected, consistent with humoral response characteristic of type 2 predominance. Antibody titers to influenza B may have been influenced by dominant circulation of this subtype in 2000. Viral-specific IgE, a relevant proxy for in vivo type 2 response, was not assessed [15] . Our findings highlight differences in the cytokine response and type 1:type 2 balance between previously vaccinated and unvaccinated persons. Differences between ORS-affected and -unaffected persons should be investigated, with larger sample sizes, ultrasensitive assays, and detailed kinetic studies. Characterizing the immune response to inactivated influenza vaccine and the underlying mechanism for ORS is of considerable public health importance, particularly as immunization campaigns are expanded to include more and younger persons each year.
